Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin

NCT05504252 is registered in ClinicalTrials.gov with University Hospital, Akershus as lead sponsor.

NCT NCT05504252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05504252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
Lead sponsor
University Hospital, Akershus
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 5, 2022
Completion date
March 1, 2028
Enrollment
80 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, mucinous adenocarcinoma, signet ring cell adenocarcinoma